ReviewFrontiers in pediatrics2026
Efficacy of zinc sulfate in neonatal hyperbilirubinemia: a meta-analysis of randomized controlled trials.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous investigations into the impact of oral zinc sulfate on serum bilirubin levels of newborns have yielded conflicting results. This meta-analysis aimed to clarify the efficacy of zinc sulfate in infants with hyperbilirubinemia by combining the evidence from published randomized controlled trials (RCTs). Methods: In this systematic review, PubMed, Embase, Cochrane CENTRAL, Scopus, and Web of Science were searched in August 2024, with an update on 25 October 2025, for the RCTs investigating zinc sulfate in infants with hyperbilirubinemia. The primary outcome was the change in total serum bilirubin (mg/dL). Mean difference (MD) with 95% confidence interval [95% confidence interval (CI)] was used to estimate the overall effect of the outcomes. A random-effects model was used to pool the results. Results: A total of 14 RCTs comprising 1,405 infants were analyzed. Zinc sulfate significantly reduced bilirubin levels at 24 h [MD: -1.12 mg/dL, 95% CI (-1.73; -0.52), Conclusion: This meta-analysis showed that zinc sulfate may reduce total serum bilirubin levels in full-term, normal-birth-weight infants during the first 4 days with a modest effect. However, this conclusion is limited by the high heterogeneity and low certainty of evidence. There was no significant reduction in phototherapy and hospital stay durations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.